Rein Therapeutics Inc. (NASDAQ:RNTX) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Rein Therapeutics Inc. (NASDAQ:RNTX) have been given a consensus recommendation of “Hold” by the four brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $6.00.

A number of analysts recently commented on RNTX shares. Maxim Group began coverage on Rein Therapeutics in a research note on Monday, July 20th. They issued a “buy” rating and a $4.00 price target for the company. HC Wainwright reissued a “buy” rating on shares of Rein Therapeutics in a research report on Tuesday, August 18th. Weiss Ratings lowered shares of Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. Finally, Wall Street Zen raised shares of Rein Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th.

Rein Therapeutics Price Performance

Shares of NASDAQ:RNTX opened at $0.79 on Tuesday. The stock’s 50-day moving average is $0.82 and its 200 day moving average is $1.07. The company has a market cap of $68.24 million, a PE ratio of -0.46 and a beta of 1.37. Rein Therapeutics has a 1 year low of $0.69 and a 1 year high of $2.18.

Rein Therapeutics (NASDAQ:RNTX) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.17. Analysts expect that Rein Therapeutics will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Rein Therapeutics

Institutional investors have recently bought and sold shares of the stock. Sequoia Financial Advisors LLC purchased a new stake in Rein Therapeutics in the second quarter worth about $260,000. Velan Capital Investment Management LP purchased a new position in shares of Rein Therapeutics during the 2nd quarter worth approximately $1,768,000. Sigma Planning Corp raised its position in shares of Rein Therapeutics by 41.0% in the 1st quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock worth $453,000 after acquiring an additional 101,400 shares in the last quarter. Chicago Partners Investment Group LLC raised its position in shares of Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Voss Capital LP raised its position in shares of Rein Therapeutics by 59.2% in the 4th quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock worth $4,923,000 after acquiring an additional 1,577,437 shares in the last quarter. 90.89% of the stock is owned by institutional investors.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.